NT Health Research and Publications Online

Title
PepSeq as a highly multiplexed platform for melioidosis antigen discovery and vaccine development.
Publication Date
2025-07-03
Author(s)
Elko, Evan A
Williamson, Charles H D
Green, Heather R
Gates-Hollingsworth, Marcellene A
Nelson, Georgia A
Pandit, Sujata G
Mead, Heather L
Allender, Christopher
Woerle, Celeste
Mayo, Mark
Currie, Bart
AuCoin, David P
Altin, John A
Keim, Paul
Settles, Erik W
Ladner, Jason T
Affiliation
The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, United States.
The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, United States.
Department of Microbiology and Immunology, University of Nevada, Reno School of Medicine, Reno, NV, United States.
Department of Microbiology and Immunology, University of Nevada, Reno School of Medicine, Reno, NV, United States.
The Translational Genomics Research Institute, Flagstaff, AZ, United States.
Department of Microbiology and Immunology, University of Nevada, Reno School of Medicine, Reno, NV, United States.
The Translational Genomics Research Institute, Flagstaff, AZ, United States.
The Translational Genomics Research Institute, Flagstaff, AZ, United States.
Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia.
Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia.
Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia.
Infectious Diseases Department and Northern Territory Medical Program, Royal Darwin Hospital, Darwin, NT, Australia.
Department of Microbiology and Immunology, University of Nevada, Reno School of Medicine, Reno, NV, United States.
The Translational Genomics Research Institute, Flagstaff, AZ, United States.
The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, United States.
The Translational Genomics Research Institute, Flagstaff, AZ, United States.
Department of Biological Sciences, Northern Arizona University, Flagstaff, AZ, United States.
The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, United States.
Department of Biological Sciences, Northern Arizona University, Flagstaff, AZ, United States.
The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, United States.
Department of Biological Sciences, Northern Arizona University, Flagstaff, AZ, United States.
Subject
Burkholderia pseudomallei
GroEL
PepSeq
epitope
highly multiplexed serology
melioidosis
vaccine
MESH subject
Melioidosis
Burkholderia pseudomallei
Humans
Antigens, Bacterial
Vaccine Development
Antibodies, Bacterial
Bacterial Vaccines
Peptide Library
Type of document
Journal Article
Entity Type
Publication
Abstract
Vaccination aims to prevent or mitigate disease by priming the immune system prior to infection. While historical vaccine development relied mostly on trial-and-error, modern approaches have become more directed. By leveraging our growing understanding of pathogen biology and immune correlates of protection, we can design vaccines in ways that promote protective responses. However, the complexity of many pathogens (e.g., bacteria and fungi), as well as our immune responses against them, continue to present important challenges for vaccine development.Here, we demonstrate the utility of the PepSeq platform for highly multiplexed serology to both broadly and finely characterize antibody responses against complex pathogens, using the bacterium, , as a case study.We designed and synthesized three diverse pools of DNA-barcoded peptides (i.e., PepSeq libraries) and used them to characterize antibodies against a variety of proteins.Epitope-resolved antibody binding profiles were generated for 85 individuals with culture-confirmed melioidosis, 89 US blood bank controls, and 6 monoclonal antibodies. Using these data, we identify novel B cell antigens/epitopes and finely characterize the epitopes of three monoclonal antibodies against the GroEL protein.Highly multiplexed serology platforms, like PepSeq, enable more comprehensive characterization of antibodies, both polyclonal and monoclonal, which can aid in the development of vaccines, diagnostics and therapeutics, even for pathogens with large, complex genomes.
Link
Citation
Front Immunol . 2025 Jul 3:16:1605758. doi: 10.3389/fimmu.2025.1605758. eCollection 2025.
ISSN
1664-3224
Pubmed ID
https://pubmed.ncbi.nlm.nih.gov/40677719/?otool=iaurydwlib

Files:

NameSizeformatDescriptionLink